Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc.verified

RXRX

Price:

$9.16

Market Cap:

$2.11B

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; ...[Read more]

Industry

Biotechnology

IPO Date

2021-04-16

Stock Exchange

NASDAQ

Ticker

RXRX

The PE Ratio as of May 2024 (TTM) for Recursion Pharmaceuticals, Inc. (RXRX) is -5.62

According to Recursion Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.62. This represents a change of 4.36% compared to the average of -5.39 of the last 4 quarters.

Recursion Pharmaceuticals, Inc. (RXRX) Historical PE Ratio (quarterly & annually)

How has RXRX PE Ratio performed in the past?

The mean historical PE Ratio of Recursion Pharmaceuticals, Inc. over the last ten years is -21.99. The current -5.62 PE Ratio has changed 2.46% with respect to the historical average. Over the past ten years (40 quarters), RXRX's PE Ratio was at its highest in in the September 2023 quarter at -4.41. The PE Ratio was at its lowest in in the June 2021 quarter at -29.09.

Quarterly (TTM)
Annual

Average

-21.99

Median

-16.38

Minimum

-47.73

Maximum

-5.65

Recursion Pharmaceuticals, Inc. (RXRX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Recursion Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 10.51%

Maximum Annual PE Ratio = -5.65

Minimum Annual Increase = -65.49%

Minimum Annual PE Ratio = -47.73

Quarterly (TTM)
Annual
YearPE RatioChange
2023-6.2510.51%
2022-5.65-65.49%
2021-16.38-51.76%
2020-33.96-28.85%

Recursion Pharmaceuticals, Inc. (RXRX) Average PE Ratio

How has RXRX PE Ratio performed in the past?

The current PE Ratio of Recursion Pharmaceuticals, Inc. (RXRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-9.43

5-year avg

-21.99

10-year avg

-21.99

Recursion Pharmaceuticals, Inc. (RXRX) PE Ratio vs. Peers

How is RXRX’s PE Ratio compared to its peers?

Recursion Pharmaceuticals, Inc.’s PE Ratio is less than Absci Corporation (-3.83), less than Affimed N.V. (-0.54), greater than Sana Biotechnology, Inc. (-5.65), less than Relay Therapeutics, Inc. (-2.71), less than Immix Biopharma, Inc. (-2.90), less than CNS Pharmaceuticals, Inc. (-0.10), less than Hepion Pharmaceuticals, Inc. (-0.15), less than Freeline Therapeutics Holdings plc (-0.57), less than AVROBIO, Inc. (2.23), less than eFFECTOR Therapeutics, Inc. (-0.21), less than Enveric Biosciences, Inc. (-0.22), less than CohBar, Inc. (-0.25), less than Ocean Biomedical, Inc. (-0.25), greater than Day One Biopharmaceuticals, Inc. (-5.71), less than Acumen Pharmaceuticals, Inc. (-3.64), less than X4 Pharmaceuticals, Inc. (-1.40), less than Inozyme Pharma, Inc. (-3.66), greater than VectivBio Holding AG (-7.94),

Build a custom stock screener for Recursion Pharmaceuticals, Inc. (RXRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Recursion Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Recursion Pharmaceuticals, Inc. (RXRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Recursion Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Recursion Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for Recursion Pharmaceuticals, Inc. (RXRX)?

What is the highest PE Ratio for Recursion Pharmaceuticals, Inc. (RXRX)?

What is the 3-year average PE Ratio for Recursion Pharmaceuticals, Inc. (RXRX)?

What is the 5-year average PE Ratio for Recursion Pharmaceuticals, Inc. (RXRX)?

How does the current PE Ratio for Recursion Pharmaceuticals, Inc. (RXRX) compare to its historical average?